Overview

Ranibizumab for Neovascularization in Sickle Cell Retinopathy

Status:
Withdrawn
Trial end date:
2011-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kresge Eye Institute
Collaborators:
Genentech, Inc.
Wayne State University
Treatments:
Ranibizumab
Criteria
Inclusion Criteria:

- Patients with sickle cell anemia and retinopathy

- Over age 18 years

- Non-pregnant

Exclusion Criteria:

- Pregnant

- Glaucoma

- Patients using anticoagulants (e.g., warfarin)

- Retinal detachment